Neuronal differentiation and functional maturation of neurons from neural stem cells induced by bFGF-chitosan controlled release system
Available methods for differentiating stem cells into neurons require a large number of cytokines and neurotrophic factors, with complex steps and slow processes, and are inefficient to produce functional neurons and form synaptic contacts, which is expensive and impractical in clinical application. Here, we demonstrated a bioactive material, basic fibroblast growth factor (bFGF)-chitosan controlled release system, for facilitating neuronal differentiation from NSCs and the functional maturation of the induced neurons with high efficiency. We illustrated by immunostaining that the neurons derived from NSCs expressed mature immunomarkers of interneurons and excitatory neurons. And we found by patch-clamp that the induced neurons exhibited diverse electrophysiological properties as well as formed functional synapses. In vivo, we implanted bFGF-chitosan into lesion area in traumatic brain injury (TBI) mice and similarly observed abundance of neuroblasts in SVZ and the presence of newborn functional neurons in injury area, which integrated into synaptic networks. Taken together, our efficient and rapid tissue engineering approach may be a potential method for the generation of functional neuronal lineage cells from stem cells and a therapy of brain injury and disease. Graphical Abstract.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Drug Delivery and Translational Research - 13(2023), 9 vom: 21. März, Seite 2378-2393 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bai, Tianyu [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
58.28 / Pharmazeutische Technologie / Pharmazeutische Technologie |
|---|---|
| Themen: |
BFGF-chitosan |
| Anmerkungen: |
© Controlled Release Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s13346-023-01322-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2144737894 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2144737894 | ||
| 003 | DE-627 | ||
| 005 | 20240410115437.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13346-023-01322-x |2 doi | |
| 035 | |a (DE-627)OLC2144737894 | ||
| 035 | |a (DE-He213)s13346-023-01322-x-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a 58.28 |2 bkl | ||
| 100 | 1 | |a Bai, Tianyu |e verfasserin |0 (orcid)0000-0002-9598-8191 |4 aut | |
| 245 | 1 | 0 | |a Neuronal differentiation and functional maturation of neurons from neural stem cells induced by bFGF-chitosan controlled release system |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Controlled Release Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Available methods for differentiating stem cells into neurons require a large number of cytokines and neurotrophic factors, with complex steps and slow processes, and are inefficient to produce functional neurons and form synaptic contacts, which is expensive and impractical in clinical application. Here, we demonstrated a bioactive material, basic fibroblast growth factor (bFGF)-chitosan controlled release system, for facilitating neuronal differentiation from NSCs and the functional maturation of the induced neurons with high efficiency. We illustrated by immunostaining that the neurons derived from NSCs expressed mature immunomarkers of interneurons and excitatory neurons. And we found by patch-clamp that the induced neurons exhibited diverse electrophysiological properties as well as formed functional synapses. In vivo, we implanted bFGF-chitosan into lesion area in traumatic brain injury (TBI) mice and similarly observed abundance of neuroblasts in SVZ and the presence of newborn functional neurons in injury area, which integrated into synaptic networks. Taken together, our efficient and rapid tissue engineering approach may be a potential method for the generation of functional neuronal lineage cells from stem cells and a therapy of brain injury and disease. Graphical Abstract | ||
| 650 | 4 | |a Neural stem cells | |
| 650 | 4 | |a bFGF-chitosan | |
| 650 | 4 | |a Neuronal differentiation | |
| 650 | 4 | |a Functional maturation | |
| 650 | 4 | |a Synaptic circuits | |
| 650 | 4 | |a Traumatic brain injury | |
| 700 | 1 | |a Duan, Hongmei |4 aut | |
| 700 | 1 | |a Zhang, Boya |4 aut | |
| 700 | 1 | |a Hao, Peng |0 (orcid)0000-0003-0879-7969 |4 aut | |
| 700 | 1 | |a Zhao, Wen |0 (orcid)0000-0003-4566-5914 |4 aut | |
| 700 | 1 | |a Gao, Yudan |0 (orcid)0000-0003-2655-1305 |4 aut | |
| 700 | 1 | |a Yang, Zhaoyang |0 (orcid)0000-0001-8313-6998 |4 aut | |
| 700 | 1 | |a Li, Xiaoguang |0 (orcid)0000-0002-2566-7907 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug Delivery and Translational Research |d Springer US, 2011 |g 13(2023), 9 vom: 21. März, Seite 2378-2393 |w (DE-627)767568605 |w (DE-600)2732593-3 |w (DE-576)393435571 |x 2190-393X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:9 |g day:21 |g month:03 |g pages:2378-2393 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s13346-023-01322-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-DE-84 | ||
| 936 | b | k | |a 58.28 |j Pharmazeutische Technologie |j Pharmazeutische Technologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 9 |b 21 |c 03 |h 2378-2393 | ||